Literature DB >> 25764018

Role for risk-scoring tools in identifying resistant pathogens in pneumonia: reassessing the value of healthcare-associated pneumonia as a concept.

Andrew F Shorr1, Marya D Zilberberg.   

Abstract

PURPOSE OF REVIEW: Resistant organisms remain a concern in patients presenting to hospital with pneumonia. Although in this setting the prevalence of various organisms such as methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa varies across the globe, patients infected with these pathogens are at increased risk for receiving an initially inappropriate antibiotic regimen - a major driver of mortality in all forms of pneumonia. The concept of healthcare-associated pneumonia (HCAP) was created to help clinicians identify persons at risk for infection with resistant pathogens, despite the onset of their infections occurring outside the hospital. However, it appears that HCAP, as currently defined, lacks adequate sensitivity and specificity for this purpose. RECENT
FINDINGS: Investigators have created various risk-scoring tools to stratify patients as to the likelihood that their infection is caused by a pathogen such as methicillin-resistant S. aureus or P. aeruginosa. These scores provide more precision at correctly segregating patients on the basis of the eventual recovery of resistant bacteria than does the HCAP syndrome. Most of these risk scores are easy to calculate and apply, and several have been externally validated.
SUMMARY: Physicians should consider adopting these tools in their approach to patients with pneumonia presenting to hospital.

Entities:  

Mesh:

Year:  2015        PMID: 25764018     DOI: 10.1097/MCP.0000000000000159

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  2 in total

1.  Healthcare-associated pneumonia: a prospective study in Spain.

Authors:  P Llinares; M C Fariñas; F Arnaíz de Las Revillas; D Sousa; C Ardunay; C García-Vidal; M Montejo; R Rodríguez-Álvarez; J Pasquau; E Bouza; J A Oteo; C Balseiro; C Méndez; N Lwoff
Journal:  Rev Esp Quimioter       Date:  2020-07-22       Impact factor: 1.553

2.  30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort study.

Authors:  Marya D Zilberberg; Brian H Nathanson; Kate Sulham; Weihong Fan; Andrew F Shorr
Journal:  Antimicrob Resist Infect Control       Date:  2017-12-06       Impact factor: 4.887

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.